Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • US Politics
    US Politics
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News

Article Tools/Herramientas de artículos

+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña




Globe NewsWire News Distribution Service

Press Release: Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Details
Category: Globe NewsWire News Distribution Service

52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of response and median PFS not yet reached


Posted: 2024-12-08 17:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | cogent | biosciences | announces


Related Bing News Search Results

Press Release: Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) - Newscast

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

Fri, 07 Mar 2025 06:00:00 GMT WALTHAM, Mass. and BOULDER, Colo., March 07, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

Fri, 07 Mar 2025 00:00:00 GMT March 07, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its ...

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Thu, 27 Feb 2025 05:59:00 GMT Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSSTop-line ...

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Wed, 26 Feb 2025 21:00:00 GMT Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced ...

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Wed, 26 Feb 2025 21:00:00 GMT Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq ... All safety data were previously reported at ASH 2024. This press release contains forward-looking statements within the ...
Blow Us A Whistle




Related Product Search/Búsqueda de productos relacionados